MA-VERISTAT
7.4.2021 14:02:07 CEST | Business Wire | Press release
Veristat , a scientific-minded, global clinical research organization (CRO), announced today that it transferred its majority ownership from Variance Development Partners to WindRose Health Investors (WindRose). WindRose invests exclusively in healthcare companies and has extensive experience across the healthcare services landscape, including outsourced biopharmaceutical services like Veristat’s.
“As a founder of Veristat, I believe that Veristat has attained the ideal investment partner who understands our philosophy, our values, and the impact we make in clinical research,” stated John P. Balser, Ph.D., President, Co-Founder, and Chief Statistical Officer of Veristat. “WindRose has a track record of successful collaboration, understands the critical nature of the scientific and therapeutic expertise we offer and will bring significant knowledge and a network of advisors to assist us as we continue to evolve.”
WindRose will support Veristat’s continued expansion to meet the needs of its growing client base around the world. This partnership will significantly benefit Veristat by complementing the leadership team with a group of diverse and knowledgeable healthcare advisors who share the same vision, culture, and focus on scientific excellence in clinical research.
“We are excited to enter into this relationship with Veristat,” said CJ Burnes, Partner with WindRose. “The Company’s clinical impact and scientific approach to partnering with companies advancing life-enhancing therapies is impressive. Their market position, stellar reputation, and leadership within biostatistics and ability to design and conduct complex clinical trials is unlike any other we have seen. In partnership with the management team and the founders, WindRose plans to contribute substantial resources to support the execution of Veristat’s strategy.”
“I am confident that our partnership with WindRose will allow Veristat’s continued focus on our core mission of helping sponsors solve the challenges that arise when developing ground-breaking products that improve and save lives through our differentiated approach to designing and executing clinical trials, clinical programs, regulatory submissions, and pharmacovigilance,” stated Patrick Flanagan, Chief Executive Officer of Veristat. “WindRose will provide us the capital and a deep network of relationships and expertise in the biotech and pharmaceutical industry as we strategically grow our company.”
Edgemont Partners acted as financial advisor to Veristat. Nutter McClennen & Fish LLP acted as legal advisor to Veristat, and McDermott Will & Emery LLP acted as legal advisor to WindRose.
About WindRose
WindRose makes equity investments in companies that operate within the services sectors of the healthcare industry. The firm focuses on companies with profitable business models and a demonstrated ability to deliver cost-effective solutions. WindRose manages over $1.2 billion in investments and is currently investing out of its fifth fund. WindRose is based in New York City and invests in companies throughout the United States.
For more information, email WindRose at info@windrose.com .
About Veristat
Veristat , a global clinical research organization (CRO), enables sponsors to solve the unique and complex challenges associated with accelerating therapies through clinical development to regulatory approval. With more than 26 years’ experience in clinical trial planning and execution, Veristat is equipped to support any development program. Our team has prepared over 100 marketing applications for approval with global regulatory authorities in the last 10 years.
Veristat's focus on novel drug development has led to success when handling the unknowns that arise across complicated therapeutic areas, such as rare/ultra-rare disease, advanced therapies, oncology, and infectious disease trials. We apply this knowledge base every day to solve any clinical program's challenges, from the simplest to the most complex. Veristat has assembled an extraordinary team of experts worldwide who have mastered therapeutic development intricacies, enabling sponsors to succeed in extending and saving lives. For more information, visit www.veristat.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210407005346/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Hitachi Expands HMAX to Accelerate the Deployment of Physical AI3.9.2026 14:00:00 CEST | Press release
New solutions for data centers, cybersecurity, and operational knowledge digitalization enable intelligent digital infrastructure Hitachi, Ltd. ("Hitachi") today announced the expansion of HMAX by Hitachi ("HMAX")*, a next-generation suite of solutions that brings the power of AI to social infrastructure. The HMAX portfolio consists of Domain-Specific Solutions tailored to industries and business operations, as well as a set of foundry solutions that span across domains. As part of this expansion, HMAX Data Center has been added as a Domain-Specific Solution for data center operators. Additionally, HMAX Cyber, HMAX Data Fabric, and HMAX AI Operations are being introduced as foundry solutions that support not only Physical AI initiatives within HMAX but also integrate and support enterprises' existing systems across different domains and environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046122/en/ HMAX Soluti
NetApp and AWS Accelerate Storage Migrations with AWS Transform3.9.2026 14:00:00 CEST | Press release
Enterprises can now migrate attached storage and database workloads directly to Amazon FSx for NetApp ONTAP with AWS Transform NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, and Amazon Web Services (AWS) today announced that AWS Transform now supports Amazon FSx for NetApp ONTAP, making it even easier for enterprises to move applications and data to AWS. AWS Transform is an agentic AI service that automates the discovery, planning, and migration of workloads to the cloud. Now generally available, customers can use AWS Transform to migrate attached storage from their on-premises and cloud estates directly to Amazon FSx for ONTAP. “Cloud migration projects often take longer and cost more than expected because customers have to move applications, servers, networking, and storage separately,” said Pravjit Tiwana, Senior Vice President and General Manager, Cloud Storage and Services at NetApp. “With AWS Transform and Amazon FSx for NetApp ONTAP, customers can simplify
MultiBank Group Named Most Regulated Global Financial Derivatives Institution.3.9.2026 13:47:00 CEST | Press release
MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903046526/en/ MultiBank Group has won the Most Regulated Global Financial Derivatives Institution Award at Money Expo India 2026. The award highlights MultiBank Group’s strong global regulatory framework as it holds more than 18 regulatory licences across five continents, including the Australian Securities and Investments Commission (ASIC), the German Federal Financial Supervisory Authority (BaFin), the Cyprus Securities and Exchange Commission (CySEC), the UAE’s Capital Market Authority (CMA), reflecting its longstanding commitment to governance, compliance and transparency. The latest recognition adds to MultiBank Group’s growing award portfolio of more than 80 international industry awards, spanning areas including financial services, trading technology, reg
Humanoids Dominate the Headlines, but Specialized Physical AI Captures Value in $18 Billion Market, Arthur D. Little’s Blue Shift Finds3.9.2026 12:07:00 CEST | Press release
Arthur D. Little’s (ADL) Blue Shift, its forward-looking institute exploring the impact of emerging technologies on business and society, today published I, Robot. Despite the hype around humanoid robots, this report finds they are still immature, compared to other areas of physical AI (autonomous and versatile robots that can perceive, decide, and act in the physical world). ADL analysis shows that humanoid robots only account for $2-3 billion of today’s overall $18 billion physical AI market. Many demonstrations are pre-programmed, remotely operated or even totally AI-generated. The study highlights that specialized physical AI offers the real opportunity for innovation and value in the short-to-medium term, and that businesses should take action now. The overall market could reach $60-$100 billion by 2030, thanks to drivers including labor shortages, shifting work preferences, increasing needs for operational resilience and productivity pressures. Countries and regions are competing
LITEON Announces Strategic Investment in Liquid Cooling Technology Company DCX3.9.2026 12:05:00 CEST | Press release
Advancing AI Infrastructure Value Chain Through Integrated Power Management and Cooling Technologies LITEON Technology (2301.TW) today announced a strategic investment in DCX POLSKA Sp. z o.o. (“DCX Liquid Cooling Systems”), a Warsaw, Poland-based provider of advanced liquid cooling systems for AI and High-Performance Computing (HPC) data centers. Upon closing of the transaction, LITEON will hold approximately 25% equity ownership in DCX Liquid Cooling Systems with a total transaction value of approximately US$176 million. The investment brings together DCX's deep expertise in liquid cooling technologies, including coolant distribution units (CDUs), facility coolant distribution units (FDUs), cold plates and immersion cooling systems, with LITEON's strengths in AI server power management, rack-level power delivery and 800VDC power architectures. Together, the two companies are positioned to deliver highly integrated power and thermal management solutions for the rapidly evolving AI inf
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom